drugset / Trial / NCT01592981
Randomised Trial in Waldenstrom's Macroglobulinaemia
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this trial is to assess tolerability and efficacy of the Bortezomib, Cyclophosphamide and Rituximab combination as initial therapy for previously untreated patients with symptomatic Waldenstrom's macroglobulinaemia.
Timeline
- Start
- 2013-01
- Primary completion
- 2017-03
- Completion
- 2020-08-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.6 mg/m2 | Subcutaneous |
| Subject | Cyclophosphamide | Other / unclassified | 250 mg/m2 | Oral |
| Comparator | Fludarabine | Small molecule | 40 mg/m2 | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |